 radiosensitizer,4
 programmed cell death ligand 1,2
 Twist1,2
 genetics,2
PD-1,7
 Ceritinib,2
 image-guided radiotherapy,2
 Total vertebrectomy,2
 migration,19
 Oligometastatic,2
 proton beam therapy,3
 neutrophil-to-lymphocyte ratio,2
 Inhalation,2
 ERCC2,2
 nanoparticles,9
 circulating tumor cells,2
 pleurodesis,2
 celecoxib,2
 Prevention,4
 Nonsense-mediated mRNA decay,3
 tumor,8
 molecular dynamics,2
 Interstitial pneumonia,3
 cardiovascular disease,2
 screening,10
 Early detection,2
 macrophage,6
 Solid tumours,2
 clinical outcome,2
Combination therapy,2
genomics,2
 skeletal related events,2
 Waterpipe,2
 Radiation pneumonitis,6
Monte Carlo,3
 Synthesis,6
 Thymoma,2
 Pulmonary Hypertension,2
 next generation sequencing,2
Akt,4
 rociletinib,2
 Radon,3
Bisphosphonate,2
A549,6
 autophagy,19
 granuloma,3
 Republic of Korea,2
 Radiography,2
Inflammation,2
 treatment outcome,2
 non small cell lung cancer,3
 supportive care,2
 general surgery,3
 proliferation,41
 Colon cancer,3
 recurrence,8
 malignant mesothelioma,7
 immunogenic cell death,2
 WI-38,2
 squamous cell lung carcinoma,2
 Tumor metastasis,3
bronchoscopy,4
 chromosomal instability,2
 Stereotactic radiotherapy,4
 personality,2
 small cell lung cancer,25
 nuclear factor-κB,2
 Chronic obstructive pulmonary disease,5
 Mass screening,2
 complex,6
Cervical cancer,3
azithromycin,2
Colorectal neoplasms,2
 T790M,16
 lysosome,2
A549 cell,2
 PARP1,2
 Cancer metabolism,2
 stroke,2
 local,2
 VEGF,14
 RB1,3
Diaphragm,2
 India,2
 qualitative research,4
 histone deacetylase inhibitor,2
 PubChem CID,3
 mouse,4
carcinoid,2
acute lung injury,2
 Exosomes,2
 Transformation,5
 comorbidity,5
 Programmed death ligand 1,2
ADC,3
PTEN,2
 chronic obstructive pulmonary disease,3
 hypoxia,7
 Non small cell lung cancer,2
 Cardiotoxicity,3
 cytotoxic activity,2
 sputum,2
 Tumor marker,5
 pulmonary adenocarcinoma,3
 radiology,2
 nose and throat/otolaryngology,3
CREB,2
 peripheral blood,2
AKT,6
 respiratory,2
Indocyanine green,2
Immune checkpoint inhibitor,5
 Tumor-associated macrophage,2
GGO,2
 integrin,2
 photodynamic therapy,4
Epidemiology,5
 Minimally invasive thoracic surgery,2
Anticancer agents,2
 gene editing,2
 immunohistochemistry ,2
Epithelial mesenchymal transition,2
MRI,6
 Targeted delivery,2
 circulating tumor cells ,3
 Next-generation sequencing,10
Immune checkpoint inhibitors,2
 MDA-MB-231,2
Age,4
 Oral cancer,2
 natural products,2
 Pleomorphic carcinoma,3
SNP,3
ATM,2
 tuberculosis,3
 [18F]FDG PET/CT,2
 Cdc42,2
 Neoplasm,4
 EGFR-TKI,7
 Treatment,9
 particulate matter,3
 source model,2
 Malignant pleural mesothelioma,6
 Wedge resection,2
 Pulmonary complications,2
Alectinib,5
 neutropenia,4
DNA methylation,15
Antibacterial,2
circulating tumor cells,2
Adaptation,2
 MCF-7,2
 molecular epidemiology,2
 radiobiology,2
 fluorescence in situ hybridization,2
 platelets,3
 Lobectomy,7
 Lung resection,2
 head and neck,2
 limited resection,2
Warburg effect,2
 miR-138,2
 Regorafenib,3
Docetaxel,4
Cabozantinib,3
 Flavonoids,2
 risk factor,3
 Mental health,2
Cancer screening,4
 Lung SBRT,3
Breast,4
 Thymus,2
PET,8
RET,2
 Metastases,6
NET,3
 Risk stratification,3
Cytokine,2
BED,2
 lung,33
MicroRNAs,3
 mammalian target of rapamycin,2
 histopathology,3
acid,2
 talc,2
 FAK,5
RAS,2
 UGT1A1,2
 Embolization,2
 S-1,2
 JAK3,2
KEAP1,2
 RASSF1,2
 Prophylaxis,2
 visceral metastasis,2
Lung,7
 next-generation sequencing,10
 xenograft,5
 Sorafenib,2
 Dice similarity coefficient,2
 mass spectrometry,4
 metabolism,5
 Docking study,2
Aflibercept,2
 adenocarcinoma,10
 Trametinib,3
 virtual screening,5
 regression,2
 lung adenocarcinoma,53
 neuroendocrine tumors,3
 peptide vaccine,2
 Targeted therapy,16
 Nanoparticle,2
ICAM-1,2
 malignancy,3
 Cytokine-induced killer cells,2
VOCs,2
 octreotide,3
 Radiosurgery,5
 pituitary adenoma,2
 Cancer,40
 Radiofrequency ablation,4
 Met,2
 pain,3
 SRC,2
Colon cancer,3
 nicotine,4
 mucinous,2
 MET inhibitor,3
 pharmacogenomics,2
 pathology,8
 Cytokine,3
Cancer,58
Apoptosis,27
 DJ-1,2
 Training,2
 MET,10
Efficacy,3
 T cells,4
 Cytology,2
 Registries,2
 cancer metastasis,5
 Simulation,3
 PCR,2
 Obesity,3
 colorectal neoplasms,2
 PD-1 inhibitors,2
 preclinical model,2
adverse events,4
 surgical oncology,2
 Risk models,2
 perfusion imaging,2
CANCER,2
ALK rearrangement,4
 Non-smokers,2
cancer incidence,2
 Microwave ablation,3
 race,2
 ceRNA,2
 pancreas,2
 PET,6
 cigarette smoke,5
 Prostate cancer,8
 diet,3
 interaction,2
 epidural spinal cord compression,2
 ROS1,12
 medical education,2
 Computed tomography ,2
checkpoint inhibitors,2
 computer-aided diagnosis,2
 Quality improvement,2
Checkpoint inhibitors,2
 heme,2
 Thiosemicarbazone,2
 Carboplatin,3
 Human lung cancer cells,2
14-3-3σ,3
digital rectal examination,2
Adrenal metastasis,3
 Medicine,3
 patient selection,2
 Solitary pulmonary nodule,3
Bronchoscopy,8
 Notch,4
 long non-coding RNA,6
 Reirradiation,2
 dosimetry,4
 Classification,4
 staging,5
 selumetinib,2
 Targeting,2
PET/CT,3
 Étude observationnelle,3
 melatonin,3
 Pulmonary function,3
 promoter methylation,2
Acute myeloid leukemia,4
 Mechanism,2
 Curcumin,5
 atypical carcinoid,3
 education,2
 miRNA,8
 checkpoint inhibitors,4
 prognostic factors,4
 essential oil,3
 lung injury,2
 simultaneous integrated boost,2
 thrombospondin-1,2
 Epithelial–mesenchymal transition,2
 non-invasive,2
Carcinoid,3
 risk assessment,2
 pemetrexed,9
 Intussusception,2
EGFR,56
 Preoperative,2
Anti-cancer activity,4
 Pneumothorax,6
 signaling,4
 Crizotinib,10
 microbiota,2
 Neuroendocrine tumors,2
 HMGA2,2
 Prognostic,5
NETs,2
MSC,2
 shRNA,3
Atelectasis,2
 pulmonary delivery,2
epidermal growth factor receptor,7
 Nrf2,3
 CT screening,2
ER stress,2
 cisplatin resistance,3
CRISPR,2
atezolizumab,2
 Drug repositioning,3
 SIRT1,2
 TKI,8
 Pulmonary adenocarcinoma,5
 anemia,2
 morbidity,2
 Exercise training,2
Clinical Epidemiology,2
 carboplatin,4
 Thymic carcinoma,2
 pulmonary fibrosis,6
 Histone methylation,2
 melanoma,22
 Gamma Knife radiosurgery,2
 Signaling pathway,2
Cancer genomics,3
 lncRNAs,5
 extracellular matrix,2
A549 cells,16
 cell cycle,16
Liver metastases,2
 polymorphism,10
 heritability,2
 prognostic factor,9
 Irinotecan,2
 Radical prostatectomy,2
 Heart failure,2
 ovary,2
 Immune system,2
 Lipophilicity,2
DICER1,2
GLUT1,2
 Relapse,4
 diagnosis,24
CAR,2
JNK pathway,2
 tumor growth,4
 Pembrolizumab,11
 thyroid cancer,3
 cell death,3
Melanoma,2
 respiratory medicine,3
oncology,8
 Thoracoscopy,2
 PD1,2
 renal cell carcinoma,8
 Fluorescence in situ hybridization,2
 HIPEC,2
Cryobiopsy,2
 Survival outcomes,2
GTV,2
 prognostic biomarker,3
 Local recurrence,2
Non-small cell lung cancer,13
 PAK1,2
 Barriers,2
 Notch signaling,2
 pleural effusion,7
 mesothelin,3
 Interstitial lung disease,10
Cáncer de pulmón,3
 radiation pneumonitis,6
 radiofrequency ablation,2
 integrins,2
 Dose escalation,2
 methylation,9
 Next generation sequencing ,2
 Lipid metabolism,2
 Survivorship,7
 maintenance therapy,5
 Thoracic,4
Aptamer,2
 peptide,2
Air pollution,13
 p53,20
 Osimertinib,9
 Circulating tumor DNA,4
 Fistula,3
airway epithelium,2
 Stroke,3
 MALAT1,5
 mismatch repair,3
 inflammation,12
 Tumors,3
 durvalumab,2
 combined therapy,2
 Citral,2
 SUVmax,2
 PARP inhibitor,3
 efficacy,6
 sublobar resection,5
 Osteosarcoma,8
 Neuroendocrine,3
 Polymorphisms,2
 Cardiovascular diseases,2
 CD8+ T cells,2
HIV,3
 Carcinogenesis,5
nab-paclitaxel,2
 epithelial–mesenchymal transition,3
 Inhibition,2
 Patient-centered outcomes,2
 Pancreatic cancer,4
 Fibrosis,4
CEA,4
 Cancer stem cells,3
 stereotactic ablative radiotherapy,3
 sarcoidosis,3
 Cohort,2
 robot-assisted thoracic surgery ,2
 cell cycle arrest,2
adenocarcinoma,15
 Patient reported outcomes,2
carcinoembryonic antigen,2
 IMRT,2
 Ventilation,2
 imaging,5
 solid tumor,4
alectinib,3
 thoracoscopy,4
 Cystic fibrosis,2
 Gene 33/Mig6,2
Meningioma,2
 herbal medicine,2
 non-small-cell lung carcinoma,3
 End-of-life care,2
 fibrosis,5
 tumor invasion,2
 DNA repair,2
EGFR inhibitor,2
CTC,4
 FDG-PET,2
 cancer vaccine,2
 Emodin,2
 Pain,2
 Translation,2
Children,3
 Medicare,2
 Cancer staging,2
 epigenetics,5
 Thiosemicarbazones,2
 Small Cell Lung Cancer,4
 Macrophages,2
 Hemoptysis,2
 Epidermal growth factor receptor tyrosine kinase inhibitor,3
 endobronchial,2
anaplastic lymphoma kinase,7
 disease,2
AIDS,3
 dose calculations,2
 Lung Cancer,8
 Polymorphism,6
 Survivin,3
 radiosensitivity,4
 tumor-associated macrophages,2
 nonsmall cell lung cancer,12
 metastatic breast cancer,3
 Pulmonary toxicity,5
MMP-9,2
Cardiovascular disease,2
 RASSF1A,2
 Utilization,2
Diagnosis,5
 Meta-analysis,18
 VATS lobectomy,3
Nivolumab,2
 epidermal growth factor receptor mutation,2
 colon,3
 predictor,2
 zinc,2
 Spindle cell carcinoma,4
 caspase,2
Heterogeneity,2
 cell proliferation,11
 incidence,7
 Thoracotomy,2
 cell culture,2
Epidermal growth factor receptor,8
 Silver nanoparticles,3
 Metastatic breast cancer,2
advanced NSCLC,2
Antioxidant,2
 Cost-effectiveness,4
 tissue distribution,2
 Eosinophil,2
 physical activity,3
bone metastasis,5
 Small cell carcinoma,4
 in vivo,3
 Breast cancer,22
 Pharmacokinetics,7
Dose-escalation,2
 Refractory,3
Antiangiogenesis,3
 oxidative stress,7
 esophageal cancer,4
 nitric oxide,2
 Sarcoidosis,5
2D,2
 combination immunotherapy,3
 gender,2
CTL,2
 transforming growth factor-β1,2
 biomarkers,10
 polyamine,2
 ER stress,2
cfDNA,2
 reactive oxygen species,11
apoptosis,11
 cisplatin,13
 Quality assurance,3
 Pneumonia,4
Anorexia,2
 Esophageal neoplasms,2
 Non–small cell lung cancer ,3
 Exhaled breath,2
 Microfluidics,2
 epithelial-mesenchymal transition,14
 Safety profile,2
 Microarray,4
 HSP90 inhibitor,2
 oncology,18
 Adenocarcinoma,2
 Quality of life,13
 Brain metastases,5
 Myocarditis,2
 Surveillance,6
 Resistance,13
 c-Met,3
 neoplasia,2
 treatment,12
 Lung cancer diagnosis,3
 distant metastasis,2
 cost-effectiveness,4
 bronchopulmonary dysplasia,2
 Intensity modulated radiotherapy,2
 TNF-α,3
 loss of heterozygosity,2
 Immunosuppression,4
Competing endogenous RNA,2
 programmed death-ligand 1 ,3
 bone metastases,5
 Trachea,3
 First-line therapy,2
 ground glass opacities ,2
 Tubulin polymerization inhibitor,2
 Toxicity,14
 histological type,2
 LIFR,2
 Xuanwei,2
 Osteopontin,3
Brain metastases,18
 Gene-environment interaction,2
 Non-small-cell lung carcinoma,3
 Elderly patients,3
 Detection,2
 Epidermal growth factor receptor ,3
 sequencing,3
 radiosensitization,3
 lung cancer,430
 MEK,3
 Neoplasm metastasis,9
 molecular testing,2
 pulmonary metastasis,5
 Immune checkpoint therapy,2
cancer biology,3
 metastases,7
 heterogeneity,9
 Disease-free survival,2
 pulmonary cancer,2
 Microenvironment,4
 Angiogenesis,3
ATRA,2
 intrapulmonary metastasis,2
Immunotherapy,8
 cancer-associated fibroblasts,3
 PEComa,2
 E-cadherin,2
 colorectal cancer,12
 Proton,2
 lymph node metastasis,3
Cancer bronchique,2
CTCs,3
 invadopodia,2
 p21,3
complications,3
 lncRNA,13
 National Institutes of Health consensus,2
 Proteins,2
 growth,4
 Indole,3
 SUV,2
Body composition,3
 Ground-glass nodule,2
 cell apoptosis,3
 Pathology,7
 Lung biopsy,3
children,2
 Staging,9
 patients,2
 Epidermal growth factor receptor mutation,3
 afatinib,4
 Veno-occlusive disease,2
 EMT,24
 early detection of cancer,4
 glioblastoma,6
Angiosarcoma,2
 Cachexia,4
 poly,2
 pneumonitis,5
 Tissue microarray,2
 Mesothelioma,12
Breast neoplasms,2
 Apoptosis,18
 RNA interference,2
TKI,5
AKI,2
 Sarcomatoid carcinoma,2
 anti-angiogenesis,2
 pharmacokinetics,5
 Cetuximab,2
 prostate-specific antigen,2
cyclooxygenase-2,2
 lung neoplasm,2
 cancer registry,2
 BRAF,4
angiogenesis inhibitor,2
 ramucirumab,2
 target therapy,3
 Life expectancy,2
 Efficacy,5
 paraneoplastic syndromes,2
 South Korea,2
head and neck cancer,2
 Patient safety,2
Biomarkers,14
 CD73,2
DKK1,2
 Metastasis,60
 positron emission tomography-computed tomography,2
 Performance status,6
CCDC6,2
 lung tumor,3
 epidermal growth factor receptor,31
 Thoracic malignancies,2
EBUS,4
 SOX4,2
 bladder cancer,3
CCL2,2
Histology,2
EGFR mutations,4
 Octréotide,2
 non–small cell lung cancer,10
 Pleural mesothelioma,2
 3D,2
 Mortality,23
ABCB1,3
 mast cell,2
 insulin-like growth factor 1 receptor,2
 Whole-brain radiation therapy,2
carbon-ion radiotherapy,2
 Cirugía,2
 sarcomatoid carcinoma,2
 radiomics,5
 anti-inflammation,2
 elderly patients,3
Cancer therapy,3
 Invasion,16
Advanced cancer,3
 Récepteurs hormonaux,2
 Elderly,5
 computed tomography ,3
 direct and indirect costs,2
 General practice,3
 adults,3
circulating tumour cells,2
 myofibroblasts,2
 tomotherapy,2
 miR-155,2
 Cervical cancer,3
Cancer stem cells,3
 uniportal VATS,2
 cytotoxic chemotherapy,2
 anticancer,6
 primary health care,2
 monocytes,2
 video-assisted,2
 berberine,2
 Migration,14
 prostatic neoplasms,4
 circulating tumor DNA ,4
 Genome,2
 microfluidic,2
 Clinical trials,5
SCC,2
 Wnt,3
 mutation,13
 chemoradiotherapy,4
Bone Marrow,2
 epidemiology,11
 IHC,2
cervical cancer,3
Cytokeratin,2
 silver nanoparticles,2
 HIF-1α,3
 liposomes,2
 Mesenchymal stem cells,2
 prevention,3
 Subtype,2
 follow-up,3
18F-FDG PET,2
 Ewing sarcoma,2
 Immunotherapy,43
 small-cell lung cancer,7
 respiratory gating,2
 brain radiotherapy,2
 Mutation,9
Anaplastic lymphoma kinase,3
 Squamous,2
 Nickel,2
 ddPCR,2
PubChem CID,10
 Pathway analysis,2
 Rociletinib,2
 Adrenalectomy,3
 surveys and questionnaires,2
 programmed death-ligand 1,2
HCC,2
 stem cells,3
 Particulate matter,3
 Comprehensive genomic profiling,2
 ZEB1,5
 risk,3
Cell proliferation,6
 Iran,3
 Transcription,2
 first-line treatment,2
 thermosensitive hydrogel,2
 mice,3
Carcinogenicity,2
 hypertension,3
 Anticancer activity,3
hepatocellular carcinoma,3
 Myocardial infarction,2
 Genomics,3
 brain tumor,2
 mutant p53,3
 fluorodeoxyglucose,2
 Drug discovery,2
 pulmonary disease,3
Lung cancer surgery,8
 stereotactic body radiotherapy ,3
 lymph nodes,5
Albumin,3
 Personalized medicine,8
 Radiation therapy,17
 irinotecan,2
 Costs,2
 Tuberculosis,3
 MTT assay,2
 tumor cells,2
 peritoneum,2
 pancreatoduodenectomy,2
 Pneumoconiosis,2
 WBRT,2
 molecular mechanisms,2
 Outcomes,5
 ER,2
 Drug delivery,6
 segmentectomy,11
 Cytotoxicity,16
 outcome,4
 lung cancer stem-like cells,2
 Nutrition,2
 minimally invasive therapy,2
 carcinoma,4
 Geriatric oncology,3
 MRI,2
 micro RNA,4
 Positron-emission tomography,4
 Review,7
TKIs,2
 Mutations,3
 Rectal cancer,3
 early detection,2
Asbestos exposure,3
 Pulmonary nodules,5
 Comorbidity,5
 awareness,2
lobectomy,4
 cancer stem cells,4
 gene delivery,3
 Prognosis,63
 non-small cell,3
 Nasopharyngeal carcinoma,2
Computed tomography,9
 tumor metastasis,4
 Metformin,4
Cancer bronchique non à petites cellules,2
Interstitial lung disease,3
 Liquid biopsy,12
 social determinants,2
 tyrosine kinase inhibitors ,2
Cancer immunotherapy,2
 tuberous sclerosis complex,2
 treatment patterns,3
 SABR,4
 MAPK,2
 exosomes,4
 typical carcinoid,3
 Wnt signaling,6
 proteomics,4
 video-assisted thoracoscopic surgery,4
 chemotherapy,50
 Lung,34
Adenocarcinoma,33
 cytotoxic T cells,2
 Lung surgery,2
 Bone metastasis,2
 dendritic cell,2
HER2,5
 tumor microenvironment,10
 Response rate,2
 France,3
Cardiac toxicity,2
 Kras,2
Video-assisted thoracoscopic surgery ,9
 temozolomide,2
 mesenchymal stem cells,2
 epithelial-to-mesenchymal transition,3
 lung metastases,4
 gold nanoparticles,2
 shared decision making,4
Non-small-cell lung cancer,5
 Progression-free survival,8
 progression,3
 Therapy,5
 Health inequalities,2
 EBUS,2
 Alectinib,4
 somatic mutation,2
Brain,2
 Diversity,2
 motion management,3
 immune checkpoint inhibitor,7
 breast,3
 Radioresistance,4
 patient-derived xenograft,3
Drug resistance,7
 LUNG CANCER,2
 Psycho-oncology,2
 Pleurectomy/decortication,2
 pulmonary,5
 tumor heterogeneity,4
 telomere length,2
 Missing data,3
 tumor suppression,2
 Wnt/β-catenin,2
 bronchoalveolar lavage,2
 Epidemiology,13
 early stage,2
 Octreotide,3
 Tobacco and the lung,3
Bleomycin,3
 pleuropulmonary blastoma,3
 isolated ACTH deficiency,2
 Mortalité,2
 MicroRNA,11
 lung neoplasms,11
 Segmentectomy,5
IMRT,6
 Molecular targeted therapy,6
 NMR,2
RNA-sequencing,3
 whole brain radiotherapy,2
 minimally invasive,4
 kinases,2
CT,10
 tumorigenesis,5
 asthma,4
 Photothermal therapy,2
 CTLA-4,2
 non-small cell lung carcinoma ,2
 third generation EGFR-TKI,2
 macrophages,5
Cancer registry,2
CBCT,3
 cancer metabolism,2
 icotinib,4
 hypermutation,2
 tumor suppressor,3
ctDNA,7
 Epithelial-to-mesenchymal transition,4
 thrombosis,3
 neoadjuvant therapy,3
 Polypyridyl,2
 lung development,3
 cancer immunotherapy,6
 organs at risk,2
Carboplatin,2
 hemoptysis,2
 Pyrazole,2
Combination,2
 intrahepatic cholangiocarcinoma,2
 Lung metastasis,4
Crizotinib,5
 Wnt/β-catenin signaling,3
 Therapeutic target,2
 immune escape,2
II,11
 Colitis,2
 Public health,4
 ULK1,2
 combination therapy,5
 I,2
 thoracotomy,5
 pulmonary metastasectomy,2
 CYFRA 21-1,2
 Esophagectomy,2
 Ultrasonography,2
 itraconazole,2
 Machine learning,3
Chemoresistance,3
ERCC1,3
 programmed death-1,2
 Liver metastases,3
Afatinib,9
 Metabolism,2
 invasive fungal infection,2
 type 2,2
Pneumonectomy,2
 Precision medicine,7
Endobronchial ultrasound ,2
 Receptor tyrosine kinase,2
 non‐small cell lung cancer,2
 Quantification,3
 minimally invasive surgery,7
type 1,2
 Brachytherapy,2
IGRT,2
 Tumor microenvironment,7
 biosensor,2
 Deep learning,2
 immune checkpoint,2
 Supportive care,4
CTLA-4,7
 Muscle wasting,2
 pleura,2
 Volatile organic compounds,2
 Neoplasm Metastasis,2
 miRNAs,2
 Therapeutics,2
 Pesticide,2
 squamous,2
 Stereotactic body radiation therapy,5
 X-ray computed,4
 pneumonia,3
 radiolabelling,2
 Colorectal cancer,10
 distress,2
 YAP1,3
 Long-term survival,3
lung metastasis,2
Complication,3
 primary care,5
lncRNAs,2
 NGS,5
 transesophageal echocardiography,2
 Molecular biology,2
 neoantigen,2
 cancer risk,2
 TTF1,2
dermatology,2
 Gold nanoparticles,2
 mTORC1,2
 lung resection,3
 lipid metabolism,2
 elderly,5
 Docetaxel,3
 P-glycoprotein,4
 feature extraction,2
 leptomeningeal metastases,4
 magnetic nanoparticles,2
 leptomeningeal metastasis,2
 Primary bone tumor,2
Anti-PD-1,2
ROS,3
 tyrosine kinase inhibitor,11
 Sarcopenia,2
Angiogenesis,9
Bone metastasis,4
 Harm reduction,2
Adverse events,3
 hypophysitis,2
 neuroblastoma,4
 detection,2
 Relative survival,2
 malignant pleural mesothelioma,2
afatinib,3
 chemoresistance,5
 Smoking cessation,8
 cytokines,6
 hematopoietic stem cell transplantation,2
 Gene,2
 trends,2
 Hazard ratio,2
 metabolomics,5
 crizotinib,16
 cancer,70
 microwave ablation,2
 Pulmonary metastasectomy,3
 renal cancer,2
FDG,4
 Screening,11
 mixed micelles,2
 curcumin,2
breast cancer,12
Cytotoxicity,3
 Nanoparticles,4
 EML4-ALK,4
 feasibility,3
 registry,2
 HeLa,2
 STAT3,8
Carcinoma,13
 CD8,2
Brain metastasis,9
 cancer control,2
Lobectomy,7
AZD9291,2
 Prognostic factor,4
AML,2
 Proliferation,16
 KRAS mutation,3
 glioma,3
 Phase I,2
 Subtypes,2
 Malignant pleural effusion,2
 apoptosis,58
 Cadmium,2
 Neuroendocrine tumours,4
Artificial neural network,2
 robotic surgery,5
 Lung toxicity,2
 hyponatremia,3
 Never-smokers,2
Choroidal metastasis,2
 radiosurgery,3
 Immune checkpoint inhibitor,2
 TNM staging,2
 disease-free survival,2
Video-assisted thoracic surgery ,5
 Erlotinib,12
 Stigma,2
Benzo[a]pyrene,2
 miR-101-3p,2
 Cell cycle,6
 Cell lines,2
 wedge resection,2
 Pulmonary hypertension,6
 air pollution,2
 prediction,2
Bronchoalveolar lavage,4
 metastasis,91
 anaerobic metabolism,2
 Survie,2
Adjuvant chemotherapy,7
 Cancer immunotherapy,2
 cell migration,2
 Spain,2
 second-line,3
 T-bet,2
 Corticosteroids,2
MiRNA,2
 Biomarker,8
 biology,4
 CT,6
 cytotoxicity,9
 innate immunity,2
CCR7,2
 Metastatic cancer,2
 HPLC,3
 synthesis,2
 pulmonary nodules,2
Epidermal growth factor receptor mutation,4
 target,2
 Reactive oxygen species,8
 Mésothéliome pleural malin,2
 Quercetin,3
 Local control,2
NK cells,2
 MMTV-PyMT,2
Epithelial-mesenchymal transition,2
 YAP,5
advanced non-small cell lung cancer,2
 Methylation,2
AMPK,3
Health-related quality of life,2
 Neoplasm invasiveness,2
 Respiration,2
2015 WHO classification,2
 molecular dynamics simulation,3
 Natural killer cells,2
MALAT1,2
lncRNA,3
Smoking,2
Complications,2
Case report,6
Cancer metabolism,2
 tumor suppressor gene,4
 Drug repurposing,2
 Circulating tumor cells,3
 free radicals,2
 single incision,2
 Quality,3
 nanomedicine,3
 Neuroendocrine tumor,3
 PM2,5
 VATS,11
LAM,2
PubChemCID,10
 Medical image,2
 Video-assisted thoracic surgery,6
 heart failure,2
 Pt,2
Acute lung injury,2
 TUMOUR BIOLOGY,2
 survival rate,2
 Multidrug resistance,6
 immune-related adverse events,2
 Large cell neuroendocrine carcinoma,2
 stage,2
 SP1,2
 resistance mechanisms,4
 thrombocytosis,2
Best supportive care,2
 Postoperative complications,2
 XRCC1,3
 positron emission tomography,9
 Pulmonary fibrosis,8
 classification,3
Ets2,2
 anaplastic lymphoma kinase,4
 Vinorelbine,3
 SBRT,12
 Receptor,2
China,5
 mitochondria,11
 salvage therapy,2
 pembrolizumab,11
 Lymph node metastasis,5
4DCT,2
 dickkopf-1,2
Elderly,7
 pneumonectomy,3
 nasopharyngeal carcinoma,2
 Radical cystectomy,2
 ERK,6
 Thoracic radiotherapy,2
 risk factors,12
 Lung adenocarcinoma,33
 Prognostic factors,6
 matrix metalloproteinase,2
 cellular senescence,2
 transforming growth factor β1,3
HOXD-AS1,2
Mesothelioma,2
CDK1,2
Circulating tumor DNA,3
 UPF1,2
 miR-34a,2
Antineoplastic agents,2
 PI3K/AKT/mTOR,2
 immune checkpoint inhibitors,5
 mediastinoscopy,2
 Weight loss,2
Alternative splicing,2
 Prophylactic cranial irradiation,3
 cytokine,4
 Cell proliferation,4
 Uniportal,2
 SREs,2
 Malignant mesothelioma,4
 nutrition,2
HIF-1α,2
 myocardial infarction,3
 vasculogenic mimicry,3
 alveolar epithelium,2
 human lung cancer cells,2
 Tumeur carcinoïde pulmonaire,2
 NLST,2
 stereotactic radiosurgery,8
 mutations,4
 EGFR mutant,2
 neuroendocrine,3
 radiotherapy,30
 metformin,7
 HER2,3
 IL-6,4
 IL-8,2
 Inflammatory myofibroblastic tumor,2
 carcinogenesis,4
 stage I,3
 Incidence,11
 mouse models,4
 COPD,3
ALDH1,2
 traditional Chinese medicine,2
 reproducibility,2
 invasive ductal breast cancer,2
EMT,25
cisplatin,2
 anti-PD-1,2
 Pronostic,2
 Lung transplantation,2
Air leak,2
 small cell lung carcinoma,3
 gastric cancer,7
 disease progression,2
 ultrasound,2
Alginate,2
 Resveratrol,4
 Radiation,12
 epithelial mesenchymal transition,2
HLA class I loss,2
 myeloid-derived suppressor cells,2
 drug resistance,14
 estrogen receptor,2
 TRIM25,2
 tumour microenvironment,2
 Cisplatin,10
 cytoskeleton,3
 NF-κB,11
 Somatic mutations,2
 osimertinib,12
 miR-33a,2
 tumor angiogenesis,2
 Lung cancer screening,10
 mouse model,2
 ctDNA,9
 formalin-fixed,2
 alectinib,11
PRRT,2
bevacizumab,6
 thymoma,3
 mitochondrial dysfunction,2
CTLA-4 inhibitors,3
Uniportal,2
Lung Cancer,3
 DNA damage response,3
 Neoplasia,2
DDP resistance,2
 calretinin,2
 anoikis,3
Geriatric Nutritional Risk Index,2
 vascular endothelial growth factor,6
 Immune checkpoint inhibitors,8
 solid tumors,4
 Cancer stem cell,3
HMGA2,2
 sorafenib,3
 Pulmonary metastases,3
 microenvironment,2
 Hematopoietic cell transplantation,3
 antiproliferative activity,2
 Tumor-infiltrating lymphocytes,2
 senescence,3
 FDG,2
 endoplasmic reticulum,2
 etoposide,2
angiogenesis,7
 occupational exposure,4
 antitumor,4
Antibody,2
 Treg,2
 phase I study,2
cohort studies,3
 indoleamine 2,2
 depression,3
 Re-irradiation,2
 toxicity,9
 oesophagus,2
 Platinum,3
 ubiquitination,2
DNA,2
False positive,2
 Occupational disease,2
 Lung cancer,307
 brain,2
 targeted therapies,2
 Lung cancer surgery,3
 drug therapy,3
 small cell,2
 spontaneous regression,2
 head and neck cancer,2
 Tomography,5
 Serum,5
 HER4,2
 asbestos,4
 type 3,2
 T cell,3
 Early diagnosis,3
 length of stay,2
Adjuvant therapy,2
 monitoring,2
 epidermal growth factor receptor tyrosine kinase inhibitor,2
 protons,2
ear,3
 single nucleotide polymorphism,6
 SRS ,3
 lymphadenopathy,2
 Thérapie ciblée,2
 Lung nodules,3
 Lung neoplasms,50
 antitumor activity,3
 Urological Cancer,2
 Children,3
 lung cancer screening,10
 cancer diagnosis,2
 quality of life,17
CD133,3
 lung carcinoma,4
G protein-coupled receptor,2
 Motion management,2
chronic obstructive pulmonary disease,2
 Stereotactic body radiotherapy ,2
 Pemetrexed,18
 cohort study,3
 NSCLC ,2
 Computed tomography,12
 lung cancer surgery,5
PD-L1 expression,2
 primary pleuropulmonary synovial sarcoma,2
Antibacterial activity,2
 prognostic value,2
 safety,7
bone metastases,2
 sunitinib,2
 erbB-1,2
 clinical trial,3
 Recurrence,10
 Genetic analysis,2
KRAS mutation,2
SEER,2
CRC,5
 Pathology Section,2
 resection,3
 pericardial effusion,3
 drug design,2
 lung cancer risk,2
 Robotic surgery,2
Antineoplastic,2
 multimodality treatment,2
 Ramucirumab,2
AXL,2
 NRF2,2
 hepatocellular carcinoma,6
 immune modulation,2
CDK4/6,2
 paclitaxel,10
 video-assisted thoracic surgery ,7
Doxorubicin,2
 Perioperative care,2
 epidermal growth factor receptor ,9
biopsy,3
 Antioxidant,3
 human,4
Driver mutations,2
 carcinogenicity,2
 thyroid transcription factor,2
 mitochondrial membrane potential,2
 lymph node,2
 Small cell lung cancer,25
 NNK,2
 Stereotactic body radiotherapy,4
 synthetic lethal,2
 docetaxel,5
Cell-free DNA,2
 quercetin,3
 tobacco,3
 monoclonal antibody,7
 cell growth,2
 Location,2
 Tomotherapy,3
 Radiomics,5
 effectiveness,3
 uncommon mutation,2
 Uniportal VATS,4
 cancer therapy,2
 response,2
 quantitative proteomics,2
 Bleomycin,2
 gemcitabine,6
 Prognostic marker,2
NF-κB,3
 acetylation,2
 Cancer therapy,2
 Heart,2
 anatomic segmentectomy,2
 molecular docking,6
 Rehabilitation,4
 breast cancer,39
 Pneumonitis,4
 isolated skeletal muscle metastasis,2
 triple-negative breast cancer,2
ALK,49
Atrial fibrillation,3
E-cadherin,3
gastrointestinal surgery,2
 Pleuroparenchymal fibroelastosis,2
 Anticancer,6
 pulmonary neuroendocrine tumors,2
 Liposomes,2
expression,2
Lung adenocarcinoma,8
Dosimetry,2
External validation,2
 tyrosine kinase inhibitors,20
Cohort study,2
anti-tumor activity,2
BRCA1,2
Abdomen,2
 Inhibitor,3
ALK inhibitor,3
 Nintedanib,4
 ErbB3,2
A/J mice,2
 liver,5
 Chemotherapy,19
 Genetics,2
 locoregional recurrence,2
Small cell lung cancer,2
 Sarcoma,4
 local recurrence,2
4D-CT,3
 acquired resistance,8
Cisplatin,4
Colorectal cancer,8
 Liver resection,2
Feline,2
Liquid biopsy,5
 Non‐small cell lung cancer,4
 cancer vaccines,2
 Carcinoma,4
 Clusterin,2
 Antiproliferative activity,2
 lung infection,3
 Micropapillary,2
 lung lobectomy,2
Robotic,2
 Temozolomide,2
 Gemcitabine,2
 nanoparticle,2
 calreticulin,2
 Geriatric,2
 primary lung cancer,2
 L858R,2
 pre-metastatic niche,2
 snoRNA,2
lactic-co-glycolic,2
bioinformatics,3
 Risk factors,7
 Epigenetics,6
 Cancer screening,3
 ATP,2
 Pathological subtype,2
KRAS,11
Invasion,5
 Splenectomy,2
Hepatocellular carcinoma,4
 Graphene oxide,2
 Stage,2
 Cutaneous metastasis,2
 Systematic review,3
 small cell carcinoma,2
 Non-small cell lung cancer,119
 3,3
 RAS,4
Bevacizumab,10
 phosphoproteomics,2
 fibroblast,3
 genomics,3
 prostate cancer,13
VEGF,2
 syndrome,2
 phosphatase,2
 Thoracic surgery,13
 carbon nanotubes,2
Asthma,5
 single-nucleotide polymorphisms,2
 erlotinib,13
 PET/CT,11
 Photodynamic therapy ,2
 outcomes,5
 Young patients,2
 PI3K inhibitor,3
Cancer cachexia,3
c-MET,2
 epithelial to mesenchymal transition,3
 qualitative,3
Follow-up,4
 dyspnea,2
 Cohort study,2
 molecular imaging,2
 clinical trials,3
RATS,4
VATS,38
 symptoms,3
 adverse events,2
 MUC4,2
 cervical cancer,3
GWAS,2
 next generation sequencing ,2
MS,2
 Tumor,3
 predictive factor,2
AMD3100,2
Advanced NSCLC,4
 HIV,3
 thoracic,2
 robotic,2
 bone metastasis,3
 pulmonary resection,2
 immunotherapy,47
 T790M mutation,5
Anesthesia,2
 ipilimumab,3
 prognosis,104
 Cytoreductive surgery,2
 Gene expression,3
 Nab-paclitaxel,2
Adenocarcinoma in situ,2
 phosphorylation,2
 pulmonary function tests,2
 doxorubicin,3
 Acquired resistance,3
 caspase-3,2
Breast cancer,31
 Radiothérapie,3
 Solid tumour,3
 metastatic disease,2
CDC6,2
III,2
chemotherapy,17
 Ovarian cancer,3
2-,2
 VEGFR-2,2
 Panitumumab,3
 NADPH oxidase,2
 Case-control study,2
Autopsy,3
 endometrial cancer,2
 predictive biomarker,3
 Guideline,2
 pulmonary emphysema,2
 SRB assay,2
 bevacizumab,8
 glycolysis,4
Cancer metastasis,2
 insulin-like growth factor,3
IGF-1R,3
 VEGFR,3
BRAF,5
 cancer biology,3
 molecular,2
 histology,2
GM-CSF,2
 Interstitial fluid pressure,2
 Pulmonary,5
PDT,2
comorbidity,2
 stereotactic body radiotherapy,4
FISH,4
 epithelial–mesenchymal transition ,2
 smokers,2
 Immunomodulatory,2
 mortality,11
 review,7
 first-line,2
 microRNA,18
 SEER,2
 aurora kinase,2
 idiopathic interstitial pneumonia,2
 Metastatic,2
 non-small-cell lung,7
 MMP-9,2
 Paraneoplastic syndrome,3
ATR,2
 HSP90,2
Asbestos,4
 plasma,5
 epidermal growth factor,4
 machine learning,2
 Mouse,2
 TGF-β1,5
 multiple myeloma,3
 inhalation exposure,2
chemoradiotherapy,2
 Hypoxia,12
 matrix metalloproteinases,2
ROS1,3
 lung squamous cell carcinoma,4
 PTEN,7
 non-small cell lung cancer ,22
 SHOX2,2
 uniportal,2
-positron emission tomography ,2
 drug delivery,9
DNA repair,2
Gefitinib,2
Chinese,2
 Oncogenic drivers,2
 Nanomicelles,2
 Gene mutation,2
 MMP-2,2
 Stool DNA,2
 focal adhesion kinase,2
 predictive factors,2
TEM,3
 Tumor heterogeneity,5
 leptomeningeal carcinomatosis,3
 targeted delivery,2
 NSCLC,213
 nivolumab,26
 lung transplantation,6
 targeted therapy,27
 drug discovery,2
 Ubiquitination,2
Non-small cell lung carcinoma,2
 Ras,2
Chemoradiation,2
 Endobronchial ultrasound,3
EPID,2
 Validation,3
 therapy,8
 NK cells,3
 Lung function,2
FOXO3a,3
 autoantibodies,2
Non-small cell lung cancer ,5
 Everolimus,2
 lung cancer ,7
TRAIL,3
 Sublobar resection,2
animal models,2
 radiation necrosis,2
 Metabolomics,2
 Tumor biology,3
 p16,3
 radioresistance,3
 Pulmonary nodule,4
 Platinum-based chemotherapy,2
 Tyrosine kinase inhibitors,12
 copy number alteration,2
A549/DDP cells,2
Cancer cells,2
EGFR-TKIs,4
 Bevacizumab,2
 Lymphoma,5
 Long non-coding RNA,2
 brachytherapy,2
18F-FDG PET/CT,3
 pazopanib,2
 pulmonary embolism,2
 immune,2
 copy number,2
Esophageal cancer,2
 ground glass opacity,2
 treatment planning,2
 Neoplasm recurrence,2
 Predictive,3
 lungs,2
 EGFR-TKIs,2
 Tumour response,2
 PM,7
asbestos,9
ABT-737,2
EGFR mutation,27
 nonsmall cell lung carcinoma,2
 In vitro,3
 Hormone receptors,2
Clinicopathological factors,2
 Hepatocellular carcinoma,10
D-dimer,3
 checkpoint inhibition,2
Cytotoxic activity,3
T cell,2
SBRT,6
 carcinoid,3
 smoking cessation,2
BSA,2
 endoplasmic reticulum stress,3
 Safety,7
 PCI,2
 tumour,2
 Solid pulmonary nodule,2
BAP1,4
 medicine,2
Cancer biomarkers,2
SCLC,9
Body mass index,2
brain metastases,7
advanced non-small-cell lung cancer,3
 surgical resection,2
 Surgical resection,3
 Exosome,2
 cost,2
 non-small-cell lung cancer ,4
 personalized medicine,6
Chronic obstructive pulmonary disease,2
 ERK1/2,2
 skin rash,2
Cryoablation,2
Chinese population,4
 lung metastasis,11
 Complication,2
biomarker,14
 programmed cell death protein 1 ,2
Erlotinib,2
 PIK3CA,3
 Non-small cell lung cancer cells,3
 cytology,3
 ovarian cancer,6
 Gefitinib,13
 PD-1/PD-L1,2
 small cell lung cancer ,4
 Combination therapy,9
 Immune-related adverse events,2
Classification,4
 rearrangement,3
 immunogenicity,4
 VMAT,3
 lung squamous carcinoma,2
 Genes,4
Immunohistochemistry,8
 Outcome,7
 Gastric cancer,6
T790M,5
 Transbronchial needle aspiration,2
 lobectomy,22
 Chemoresistance,5
 TGF-β,3
 computed tomography,4
lung adenocarcinoma,5
 Consolidation,2
 NCDB,2
 platinum,3
 Checkpoint inhibitor,2
 Biomarkers,3
 Overall survival,17
 Limbic encephalitis,2
 Urologic neoplasms,2
 Metastatic colorectal cancer,2
cell cycle arrest,2
Acquired resistance,7
 KPS ,2
 influenza vaccine,2
 liquid biopsies,3
 deep learning,2
 nickel,2
 proton therapy,2
Antiproliferative,2
 molecular biology,3
 Cell death,2
 Sp1,2
 Hypermethylation,2
 Lung carcinoma,5
Bladder cancer,2
 renal cell cancer,2
 squamous cell carcinoma,12
 learning curve,2
 Programmed death-ligand 1,3
Lung metastasis,2
3-dioxygenase,2
 p38 MAPK,2
 irAE,2
KRAS mutations,2
 wait times,2
Chemotherapy,20
 EGFR mutation,13
 anaplastic lymphoma kinase ,4
 histone modification,2
 E2F1,2
 tumor infiltrating lymphocytes,3
 tenascin-C,2
 Modeling,2
 anti-inflammatory activity,2
 cell-free DNA ,2
Anaplastic lymphoma kinase ,4
Immune checkpoints,2
 volume,2
Adjuvant,3
 Venous thromboembolism,7
epithelial-mesenchymal transition,2
 non-small-cell lung cancer,49
 radiation therapy,12
 Immunohistochemistry,20
biomarkers,12
 surgery,15
 video-assisted thoracic surgery,3
 Biomarqueurs,3
 oligometastases,2
 Ruthenium complexes,2
 Lung neuroendocrine carcinoma,2
 paraneoplastic syndrome,3
 G2/M arrest,2
 Predictive biomarkers,2
 Neoplasms,10
 tissue microarray,2
carboplatin,6
LUSC,2
 ceritinib,4
Bayesian,2
 lysyl oxidase,2
 overall survival,26
 therapeutic target,4
ERK,2
 metastasectomy,9
 transcriptome,4
 Lung nodule,3
Advanced non-small cell lung cancer,2
meta-analysis,2
 RNA-Seq,2
 Neutrophil-to-lymphocyte ratio,2
 endoscopy,2
Cetuximab,2
 PDE3A,2
 bioinformatics,2
 Somatic mutation,2
 atezolizumab,3
 Radiotherapy,27
FDG PET/CT,2
Bone metastases,2
epidemiology,5
 SDF-1,2
 differentiation,3
 RNA-seq,4
 Primary care,5
 EMMPRIN,2
 differentiated thyroid cancer,2
 Warburg effect,2
 Snail,3
Barriers,2
chronic kidney disease,2
Dyspnoea,2
 Paclitaxel,7
 Palliative care,6
 TNM classification,2
 meta-analysis,46
 synthetic lethality,4
 nintedanib,2
 influenza,2
 thymic carcinoma,4
Long non-coding RNA,2
 carcinoembryonic antigen,3
 Drug therapy,2
diagnosis,2
 expression,2
 smoking,12
chemoprevention,2
 non-small cell lung cancer,195
 positron emission tomography ,5
 Immune cells,2
 Platelets,2
Folic acid,2
 cancer screening,3
 PD,2
 skin cancer,2
 anorexia,2
 Testicular cancer,3
metastases,2
 non-small cell lung carcinoma,5
 neuroendocrine tumor,2
 early diagnosis,5
 Thyroid,3
 Positron emission tomography,15
 progression-free survival,9
Distant metastasis,2
EZH2,2
 Let-7,2
Brachytherapy,2
 Video-assisted thoracoscopic surgery,4
Circulating tumor DNA ,3
CRT,2
 nab-paclitaxel,4
 Dichloroacetate,2
 interstitial lung disease,9
Adoptive cell transfer,2
 retrospective analysis,2
 Vimentin,2
 Low dose CT,2
 sleeve lobectomy,3
 Macrophage,2
 Molecular modeling,3
 Survival,47
 NO,2
 Autophagy,5
 fine particulate matter,2
Chemoradiotherapy,8
 Video-assisted thoracic surgery ,2
CT-guided,2
 Drug resistance,9
 Lung cancer stem cells,2
 targeted drug delivery,2
 neoplasms,2
 Maintenance therapy,3
Anticancer,10
 synchronous tumors,2
 estrogen,2
FAK,2
 neutrophil,3
 Observational study,4
LUNG CANCER,2
 mechanisms,2
 p73,2
 Small-cell lung cancer,4
 Infection,4
 Cox-2,2
 ECOG,2
 circulating tumor cell,2
 Mesenchymal stromal cells,2
 Pediatrics,2
 Melanoma,10
,7443
 MMP9,2
Curcumin,2
non-small cell lung cancer,4
 KRAS,7
 gene expression,8
-2,2
 2,2
 cytotoxic,3
 Imaging,3
 MEK inhibitor,2
 Lung cancer cells,4
 systems biology,4
 Non-small-cell lung cancer,19
 cancer stem cell,2
 Pulmonary tumor thrombotic microangiopathy,3
 Akt,3
brain metastasis,4
Biomarker,29
 survival analysis,2
 Ultrasound,4
 cognition,2
 tyrosine kinase inhibitor ,3
NGS,5
 patient safety,2
 gene therapy,5
 pulmonary rehabilitation,2
 Decision analysis,2
 Stat3,4
 Ovalbumin,2
 survival time,3
 Case report,5
 surgical treatment,2
 tumor progression,2
 oligometastatic,2
 Disease,3
 Pneumonectomy,5
Hematopoietic cell transplantation,2
Wilms tumor,2
 immunohistochemistry,30
 Nsclc,2
 Skeletal-related events,2
 replication,2
 mTOR,2
 lung cancer cells,3
 inflammasome,2
 Photodynamic therapy,5
 M2 macrophage,2
 TCGA,6
 pregnancy,2
 mesothelioma,23
 PDK1,2
 Chirurgie,2
 Pulmonary metastasis,5
carcinoma,4
 tobacco smoking,2
 Sequencing,2
 PAI-1,2
 PDGFR,2
 palliative radiotherapy,2
 venous thromboembolism,3
 oncogene,2
 Chemoradiotherapy,3
Aging,2
 metronomic chemotherapy,2
 anticancer activity,2
 antigen,2
Appalachia,2
 Thyroid carcinoma,3
Autophagy,10
 Pleural effusion,2
 precision medicine,8
 Cell signaling,2
 Depression,4
erlotinib,2
 microRNAs,13
 Wnt/β-catenin pathway,3
 interstitial pneumonia,3
 DNA methylation,7
 transforming growth factor-β,3
 dendritic cells,2
uniportal VATS,2
 JNK,2
 Women,2
 repurposing,2
 Immune checkpoint,2
 extrathoracic metastasis,2
 Inflammation,13
 SURGICAL PATHOLOGY,2
 prophylactic cranial irradiation,2
 human biology,2
 HCC,3
 IMPT,2
 Late effects,4
 Nanomedicine,2
Bronchial carcinoid,2
Kras,2
 Ki-67,4
 Cytotoxic activity,2
 Lymphadenectomy,2
 FISH,4
Incidence,2
 relative risk,2
ELISA,2
 cfDNA,2
 Lung squamous cell carcinoma,4
 pancreatic cancer,9
cancer,18
 Disparities,2
 FDG PET/CT,2
 pharmacogenetics,2
 lung nodule,2
 head and neck squamous cell carcinoma,3
 idiopathic pulmonary fibrosis,6
 MRI-guided radiotherapy,2
IHC,5
 video-assisted thoracoscopic surgery ,6
 vorinostat,2
 cardiotoxicity,2
 CYP3A4,2
 Exercise,5
S-1,3
 calmodulin,2
 Polysaccharide,3
 FFPE,2
 vitamin D,2
Lung cancer,75
 brain metastasis,9
 Multiple primary lung cancer,2
 PI3K,3
 Autoimmune,2
 osteosarcoma,10
adjuvant therapy,2
 Afatinib,3
 cyclophosphamide,2
 DNMT1,3
 CXCR4,4
Adenocarcinoma of lung,2
Circulating tumor cells,7
 Survival analysis,7
 Deformable image registration,2
 Nivolumab,22
 immune effects,2
 Resection,2
 HR,2
 Epithelial-mesenchymal transition,6
 Neuroendocrine carcinoma,2
 Diagnostic,3
 PD-1,18
 quality assurance,2
 immune therapy,2
 Molecular testing,2
 nanoscale microbubble,2
 Squamous cell carcinoma,14
 neutrophils,2
 NKG2D,3
 Competing risk analysis,2
PD-L1,9
 β2-adrenoceptor,2
inflammation,3
Cost-effectiveness,3
Lung-protective ventilation,2
 Malignancy,3
 liquid biopsy,20
DNA methyltransferase,2
 Heterogeneity,7
 Magnetic resonance imaging,7
lung cancer,17
depression,2
 programmed death ligand 1,2
4-thiadiazole,2
 secondhand smoke,2
 neuroendocrine carcinoma,2
 CCL2,2
Amrubicin,4
 Metabolic tumor volume,2
 survival,41
 colon cancer,5
Metastasis,5
Malignant pleural mesothelioma,2
 squamous lung carcinoma,2
 β-catenin,9
 Oncology,15
 Microcapsule,2
 Non-small cell lung cancer ,5
 Lymphangioleiomyomatosis,2
COPD,15
 rearrangements,2
EGFR TKI,4
 Targeted therapies,5
EGFR-TKI,4
CXCR4,6
CXCR2,2
MDM2,3
 apatinib,3
 microparticles,2
 migration and invasion,3
 leukemia,3
 Leiomyosarcoma,2
 brain metastases,17
 large-cell neuroendocrine carcinoma,2
 Thoracic radiation therapy,2
 palliative care,13
 Brain metastasis,6
 Lung injury,2
 advanced NSCLC,3
 resistance,13
 Oligometastases,2
 anesthesia,2
 gefitinib,11
 Slug,2
 ethics,3
EBUS-TBNA,6
 aging,2
 cardiovascular risk,2
 epigenetic,4
 liver metastases,2
CIP2A,2
 Thymidylate synthase,2
 Surgery,41
 Lung neoplasm,6
 Surgical outcomes,2
 Uncommon mutation,2
 cytopathology,3
 pH-sensitive,2
 Radiosensitivity,2
 Mitochondria,3
 Epidermal growth factor receptor,17
Carcinogenesis,4
 Cancer neuroendocrine pulmonaire,2
 Skp2,2
 fusion gene,2
 biomarker,31
Autoantibody,3
Anticancer activity,6
PRC1,2
Pseudomonas aeruginosa,3
 OPG,2
 osteopontin,2
 performance status,4
 SNP,3
 neoplasm metastasis,2
 extracellular vesicles,3
 Remission,2
cancer genomics,2
 arrhythmia,2
 MEG3,2
 EGFR,56
 pulmonary metastases,4
 invasiveness,2
Computer-aided diagnosis,2
 glutamine,2
 stereotactic body radiation therapy,3
 simultaneous surgery,2
Gemcitabine,3
 Colorectal neoplasms,2
 In vivo,2
 PD-L1,42
 China,8
 microRNA-200c,2
 Eastern Cooperative Oncology Group,2
3-,2
 thoracic surgery,11
intensity-modulated radiotherapy,2
 vandetanib,2
 Karnofsky Performance Scale,2
 lung adenocarcinomas,2
Breast carcinoma,2
 magnetic resonance imaging,5
epidermal growth factor receptor mutation,2
 adhesion,2
 Programmed death 1,3
Apatinib,3
Cavitation,2
 Smoking,17
 Non–small cell lung cancer,17
Immunology,2
 rivaroxaban,2
 Diagnosis,13
 Non-small cell lung carcinoma,12
 ROS1 rearrangement,3
 Head and neck cancer,2
Bronchi,3
 telomerase reverse transcriptase,2
 Esophageal cancer,8
 public health,2
 nomogram,2
 miR-181a,2
 anti-tumor,2
 Qualitative research,2
 Tobacco,3
 Lung diseases,2
 genotype,2
 Non-Small Cell Lung Cancer,3
 medical imaging,2
Adverse event,2
 Geriatric assessment,2
 bronchoscopy,6
 Gene polymorphism,2
 flattening filter free,2
 MET amplification,2
NSCLC,85
 insurance,2
 Tyrosine kinase inhibitor,7
ASCL1,2
 systematic review,4
 endostatin,3
 Long-term follow-up,2
 Surgical technique,2
 psychometrics,2
 complexes,7
 diseases,2
 necrosis,2
 thoracoscopic,2
 IGF1R,2
 Bronchoscopy,5
 siRNA,4
 RET,4
 Doxorubicin,4
 Oxidative stress,6
 Stereotactic ablative radiotherapy,2
 uric acid,2
 angiogenesis,12
 therapeutics,2
 Surgical treatment,2
 texture analysis,3
 invasion,28
 Predictive factor,2
 diagnostics,2
Cancer vaccine,2
 pulmonary nodule,2
Lung neoplasms,9
cell-free DNA,2
 F344,2
 OSCC,2
Genomics,2
 systemic therapy,2
Gastric cancer,5
DNA damage,4
 extracellular signal-regulated kinase,2
 SCLC,15
 Camptothecin,3
APC,2
 Complementary medicine,2
 induction therapy,4
 ROS,12
 dexamethasone,2
Biosensor,3
 EGFR mutations,4
 Renal cell carcinoma,3
 lung diseases,4
 Glycolysis,2
 cell free DNA,2
 salvage,2
 TSC,3
 Lung metastases,6
 Survival rate,2
ARS,2
 non-small cell lung,6
 Histology,2
